Suramin, an Active Drug for Prostate Cancer: Interim Observations in a Phase I Trial

Abstract

Future trials should address the role and necessary extent of therapeutic drug monitoring; the optimal plasma drug concentration range and duration of therapy; and the activity of suramin in combination with other agents, in earlier stages of prostate cancer, and in other tumor types.